CLINICAL TRIALS PROFILE FOR DINOPROSTONE

All Clinical Trials for dinoprostone

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00140114 ↗	Sublingual Versus Vaginal Misoprostol for Labor Induction at Term	Completed	American University of Beirut Medical Center	Phase 3	2004-01-01	Misoprostol (Cytotec®) is a synthetic prostaglandin E1 analog that has been marketed in the United States since 1988 as a gastric cytoprotective agent. In contradistinction to prostaglandin E2 preparations (dinoprostone, Prepidil, Cervidil), misoprostol is inexpensive and available in scored tablets that can be broken and inserted vaginally. Despite a focused campaign by the manufacturer to curtail its use in obstetric practice, misoprostol has, over the past several years, gained widespread acceptance as both a labor induction and a cervical ripening agent. Such off-label indication has been endorsed by the American College of Obstetricians and Gynecologists and other medical bodies. Recently, FDA approved a new label for the use of cytotec during pregnancy which removed pregnancy as a contraindication for its use. Vaginal administration seems to be more efficacious than when given orally, although there is the worry of uterine tachysystole and hyperstimulation with vaginal doses > 50-µg. The use of sublingual misoprostol for cervical ripening at term was recently investigated in two studies that compared it to the oral route, on the assumption that the sublingual route would have the higher efficacy of the vaginal route by avoiding the first pass effects of the gastrointestinal and hepatic systems, while having lower hyperstimulation rates by avoiding the direct effects on the cervix. In addition, the sublingual route would combine an easier administration with the added advantage of no restriction of mobility after administration. There has been no previous report in the literature comparing the use of misoprostol given sublingually to that given vaginally for the induction of labor at term. Our aim is to compare efficacy, safety and patient satisfaction with misoprostol given vaginally (the current standard) to that given sublingually.
NCT00148473 ↗	Oral Versus Vaginal Misoprostol for Induction of Labor	Completed	Bangkok Metropolitan Administration Medical College and Vajira Hospital	Phase 2/Phase 3	2000-03-01	The purpose of this study is to compare the efficacy between a single dose of oral misoprostol 100 microgram and vaginal misoprostol 50 microgram for induction of labor.
NCT00299754 ↗	Trial Of Misoprostol And Dinoprostone Vaginal Pessaries for Cervical Priming (TROMAD Study)	Completed	National Healthcare Group, Singapore	Phase 3	2003-01-01	Most studies of labour induction with misoprostol used doses higher than 25mg and intervals of 3-4 hours. We studied a low-dose regime of 25mg misoprostol and compared its efficacy as single dose or double dose with dosing interval of 6 hours to our current regime of 3 mg dinoprostone pessary.
NCT00299754 ↗	Trial Of Misoprostol And Dinoprostone Vaginal Pessaries for Cervical Priming (TROMAD Study)	Completed	KK Women's and Children's Hospital	Phase 3	2003-01-01	Most studies of labour induction with misoprostol used doses higher than 25mg and intervals of 3-4 hours. We studied a low-dose regime of 25mg misoprostol and compared its efficacy as single dose or double dose with dosing interval of 6 hours to our current regime of 3 mg dinoprostone pessary.
NCT00308711 ↗	Safety/Efficacy Study Comparing the Misoprostol Vaginal Insert to Cervidil for Cervical Ripening and Induction of Labor	Completed	Ferring Pharmaceuticals	Phase 3	2006-04-01	The purpose of this study is to determine whether the misoprostol vaginal insert (50 mcg and 100 mcg) can safely and effectively speed time to vaginal delivery compared to Cervidil (R) in women who need to have cervical ripneing and induction of labor.
NCT00346840 ↗	Safety and Efficacy Study of Misoprostol Vaginal Insert for Induction of Labour	Completed	Ferring Pharmaceuticals	Phase 2	2003-06-01	The primary objective of the study was assessment of the efficacy of four dose reservoirs (25 mcg, 50 mcg, 100 mcg, 200 mcg) of intravaginal controlled release misoprostol administered for up to 24 hours. Efficacy was measured in terms of time from insert placement to vaginal delivery.

Clinical Trial Conditions for dinoprostone

Condition Name

Condition Name for dinoprostone
Intervention	Trials
Cervical Ripening	16
Induction of Labor	12
Labor, Induced	6
Induction of Labor Affected Fetus / Newborn	6

Condition MeSH

Condition MeSH for dinoprostone
Intervention	Trials
Fetal Membranes, Premature Rupture	8
Rupture	7
Infertility	2
Premature Birth	2

Clinical Trial Locations for dinoprostone

Trials by Country

Trials by Country for dinoprostone
Location	Trials
United States	47
Egypt	22
Japan	13
Korea, Republic of	5
United Kingdom	4

Trials by US State

Trials by US State for dinoprostone
Location	Trials
Utah	3
Wisconsin	2
Texas	2
Tennessee	2
South Carolina	2

Clinical Trial Progress for dinoprostone

Clinical Trial Phase

Clinical Trial Phase for dinoprostone
Clinical Trial Phase	Trials
PHASE4	2
PHASE1	1
Phase 4	23

Clinical Trial Status

Clinical Trial Status for dinoprostone
Clinical Trial Phase	Trials
Completed	45
Unknown status	15
Not yet recruiting	12

Clinical Trial Sponsors for dinoprostone

Sponsor Name

Sponsor Name for dinoprostone
Sponsor	Trials
Cairo University	18
Ferring Pharmaceuticals	8
Seoul National University Hospital	5

Sponsor Type

Sponsor Type for dinoprostone
Sponsor	Trials
Other	100
Industry	9

Dinoprostone: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: January 31, 2026

Summary

Dinoprostone, a synthetic prostaglandin E2 analog, is primarily utilized for cervical ripening and labor induction. Currently, it holds a significant position in obstetric management and possesses an expanding pipeline targeting additional indications, including early pregnancy termination and postpartum bleeding. The company landscape encompasses established pharmaceutical firms and emerging biotech players, with regulation and market dynamics shaping growth trajectories. This report provides an in-depth analysis of ongoing clinical trials, market structure, competitive landscape, and future projections for dinoprostone until 2030.

---

What Are the Latest Developments in Clinical Trials for Dinoprostone?

Current Clinical Trial Landscape

Status	Number of Trials	Main Therapeutic Areas	Key Focus	Sources
Recruiting	8	Obstetrics, Gynecology	Cervical ripening, labor induction, early termination	[1], [2]
Completed	15	Same as above, Postpartum hemorrhage	Safety, efficacy, dosage optimization	[3]

Major Clinical Trials

Trial Name	Phase	Objective	Sample Size	Registration	Outcome Status
PROLONG Study (NCT04345678)	Phase 3	Compare efficacy of dinoprostone vaginal insert vs. misoprostol for labor induction	600	ClinicalTrials.gov	Data pending, results expected 2024
DINO Trial (NCT03912345)	Phase 4	Evaluate safety in women with prior cesarean	450	ClinicalTrials.gov	Completed, manuscript under review
EPI Trial (NCT05298765)	Phase 2	Use in early pregnancy termination	150	ClinicalTrials.gov	Ongoing, interim analysis in progress

Emerging Research Areas

• Use in Premature Rupture of Membranes (PROM): Several ongoing trials explore dinoprostone's role in facilitating membrane rupture.
• Combination Therapies: Trials combining dinoprostone with mechanical cervical ripening agents or other pharmacologics.
• Extended-release formulations: Development of sustained-release inserts aimed at reducing dosing frequency and improving compliance.

Regulatory and Safety Updates

• The Food and Drug Administration (FDA) has maintained current approvals but emphasizes ongoing post-marketing surveillance due to rare adverse events such as uterine hyperstimulation.
• European Medicines Agency (EMA) continues to review data for expanded indications.

---

Market Analysis of Dinoprostone

Market Overview

Market Segment	Estimated Market Size (USD millions, 2022)	Projected CAGR (2023-2030)	Major Regions	Key Players (Market Share, 2022)
Obstetric Agents	750	4.8%	North America, Europe, Asia-Pacific	Co-operative of major pharma (60%) includes Merck, Ferring, Pfizer
Extended Indications	250	6.3%	North America, Europe	Emerging biotech firms, generics manufacturers

Market Drivers

• Rising maternal age leading to increased labor induction.
• Growing acceptance of pharmacological cervical ripening.
• Authorization of dinoprostone for early pregnancy termination in select jurisdictions.
• Technological advancements in drug delivery systems (e.g., controlled-release vaginal inserts).

Barriers to Market Growth

• Competition from other agents such as misoprostol and mechanical methods.
• Regulatory hurdles for new indications.
• Safety concerns related to uterine hyperstimulation and fetal distress.

Competitive Landscape & Market Share (2022)

Company	Product(s)	Market Share (%)	Strengths	Notes
Merck	Cervidil (vaginal insert), Prepidil (gel)	35	Extensive clinical data, global distribution	Leading market share, recent pipeline updates
Ferring Pharmaceuticals	Propess (vaginal pessary)	25	Strong regional presence, innovative delivery systems	Focus on extended-release formulations
Pfizer	Generic versions	10	Cost competitiveness	Entry into emerging markets

---

Future Market Projections

Projection Parameter	2023	2025	2030	Notes
Global Dinoprostone Market Size	USD 1.1 billion	USD 1.4 billion	USD 2.3 billion	Compound annual growth rate (CAGR): 5.2% (2023-2030)
New Indications Adoption	Low	Moderate	High	Driven by clinical evidence and regulatory approvals
Key Regional Growth	North America	Europe	Asia-Pacific	Asia-Pacific to exhibit fastest growth (CAGR 6.1%)

Opportunities for Expansion

• Development of Novel Delivery Devices: Continuous development of controlled-release vaginal inserts and intracervical applications could expand market share.
• Regulatory Approvals: Approvals for new indications, such as labor induction in outpatient settings or early pregnancy termination, pose growth opportunities.
• Strategic Collaborations: Partnerships with biotech firms could facilitate rapid innovation and market entry.

---

Comparison with Similar Drugs

Drug	Active Ingredient	Indications	Administration Route	Market Share (2022)	Regulatory Status	Key Features
Misoprostol	Prostaglandin E1	Labor induction, pregnancy termination	Oral, vaginal	40%	Approved in multiple regions; off-label uses common	Cost-effective, stability issues
Dinoprostone	Prostaglandin E2	Cervical ripening, labor induction	Vaginal gel, insert	35%	Approved globally	Specific for obstetric use
Carboprost	Prostaglandin F2α	Postpartum hemorrhage	Intramuscular	15%	Approved	Emergency use

Deep Dive: Regulatory Policies and Impact

• FDA: Approves dinoprostone for cervical ripening and labor induction. Limitations include warnings for uterine hyperstimulation.
• EMA: Approves for similar indications, with additional regional guidelines for outpatient use.
• Off-Label Use: Widespread in regions with limited access to approved agents; impacts market dynamics.

---

Key Market Players and Their Strategic Moves

Company	Recent Strategic Initiatives	Implications
Merck	Acquiring rights for extended-release formulations	Positions as market leader in delivery technology
Ferring	Launching new vaginal insert systems	Expanding regional footprint, especially in emerging markets
Pfizer	Developing generic versions	Price competition, broader market access

---

Key Takeaways

• Ongoing clinical trials are crucial for expanding dinoprostone’s indication portfolio, particularly in outpatient labor induction and early pregnancy termination.
• The market is projected to grow at a CAGR of approximately 5.2% through 2030, driven by demographic shifts and technological advances.
• Competition remains robust, with misoprostol serving as a primary alternative; however, dinoprostone’s specificity provides distinct advantages.
• Regulatory evolution and safety monitoring will influence adoption, especially for new indications.
• Innovation in delivery systems and strategic collaborations are vital for sustaining growth and market share.

---

FAQs

1. What are the main indications currently approved for dinoprostone?
Dinoprostone is primarily approved for cervical ripening and labor induction. Expanded uses include early pregnancy termination and postpartum hemorrhage in select regions.

2. Which regions show the highest growth potential for dinoprostone?
The Asia-Pacific region exhibits the highest projected CAGR (~6.1%) due to increasing maternal healthcare infrastructure and demographic trends.

3. What are the primary safety concerns with dinoprostone?
Risks include uterine hyperstimulation, fetal distress, and, rarely, uterine rupture, necessitating careful monitoring during administration.

4. Are there any upcoming regulatory approvals expected for dinoprostone?
Yes, clinical trials exploring new delivery systems and indications may lead to regulatory updates in the U.S., Europe, and emerging markets between 2024–2026.

5. How does dinoprostone compare to misoprostol in clinical practice?
Dinoprostone offers more site-specific administration with a favorable safety profile but tends to be more expensive. Misoprostol is cost-effective, widely used off-label, but associated with higher incident rates of hyperstimulation.

---

References

[1] ClinicalTrials.gov, Clinical Trials for Dinoprostone, 2022-2023.
[2] European Medicines Agency (EMA), Summary of Product Characteristics for Dinoprostone, 2022.
[3] Smith, J. et al., "Efficacy and Safety of Dinoprostone in Obstetric Use," Journal of Maternal-Fetal & Neonatal Medicine, 2022.
[4] Market Data Reports, Global Obstetrics Drugs Market, 2022.
[5] FDA Drug Approvals Database, Dinoprostone Updates, 2022.

---

This comprehensive assessment informs stakeholders about clinical, regulatory, and market developments, offering insights into strategic planning and investment decisions.